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have also been previously reported to express several receptors and neurotransmitters,
including corticotropin releasing hormone receptor 1 (CRF1) and gamma-aminobutyric acid
(GABA). The NI projects widely to putative neural correlates of stress, anxiety, depression,
feeding behaviour, arousal and cognition leading to speculation that it might be involved in
several neuropsychiatric conditions. On the premise that relaxin-3 expressing neurons in
the NI predominantly co-express CRF1 receptors, a novel method for selective ablation of
the rat brain NI neurons using corticotropin releasing factor (CRF)–saporin conjugate is
described. In addition to a behavioural deﬁcit in the fear conditioning paradigm, reverse
transcriptase polymerase chain reaction (RT-PCR), western blotting (WB) and immuno-
ﬂuorescence labelling (IF) techniques were used to conﬁrm the NI lesion. We observed a
selective and signiﬁcant loss of CRF1 expressing cells, together with a consistent decrease
in relaxin-3 and GAD65 expression. The signiﬁcant ablation of relaxin-3 positive neurons of
the NI achieved by this lesioning approach is a promising model to explore the
neuropsychopharmacological implications of NI/relaxin-3 in behavioural neuroscience.
& 2013 The Authors. Published by Elsevier B.V. Open access under CC BY license.1
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The nucleus incertus (NI), better known for its status as
the principal source of neuronal relaxin-3, is a brainstem
nucleus located ventral and medial to the posterodorsaltegmental nucleus (PDTg) in the pontine periventricular grey
(Burazin et al., 2002; Goto et al., 2001; Olucha-Bordonau et al.,
2003). The NI neurons were initially shown to express the
inhibitory neurotransmitter, gamma-aminobutyric acid
(GABA) (Ford et al., 1995) and have later been revealed to
b r a i n r e s e a r c h 1 5 4 3 ( 2 0 1 4 ) 1 7 9 – 1 9 0180co-express the recently discovered neuropeptide, relaxin-3
(Ma et al., 2007). This small and distinct group of neurons has
sparked off renewed interest due to its high expression of the
corticotropin releasing hormone receptor type 1 (CRF1)
(Bittencourt and Sawchenko, 2000; Potter et al., 1994), which
suggests a role of the NI in the stress response. Subsequent
studies reported the presence of other receptors in the NI, e.g.
5-hydroxytryptamine (5-HT or serotonin) receptor subtype 1A
(5-HT1A) (Miyamoto et al., 2008), and relaxin/insulin-like
family peptide receptor 3 (RXFP3) (Sutton et al., 2004). Other
neuropeptides expressed by nucleus incertus include neuro-
medin B (Chronwall et al., 1985; Wada et al., 1990) and
cholecystokinin (Kubota et al., 1983; Olucha-Bordonau et al.,
2003). Of particular interest, expression of relaxin-3 is highly
speciﬁc and most abundant in the NI and only a small
number of neurons in other nearby regions such as the
pontine raphe nucleus, periaqueductal grey and dorsal sub-
stantia nigra express relaxin-3 (Tanaka et al., 2005). As such,
the NI – serves as a key point of regulation for functioning of
the relaxin-3 neural circuitry.
The NI possibly exerts its actions through numerous
projections to several parts of the brain, including the
prefrontal cortex, medial septum (MS), hippocampus,
amygdala, hypothalamus and the raphe nuclei (Goto
et al., 2001) – areas that are implicated in various psychia-
tric conditions. Relaxin-3 binds to the RXFP3, which
belongs to the family of relaxin peptide receptors that
was recently elevated from orphan receptor status (van
der Westhuizen et al., 2008). The precise functions of theFig. 1 – Selection of CRF–saporin dose for ablation of NI neurons
cells in the NI of (A) naïve control (n¼3), (B) 21.5 ng/site CRF–sapo
(D) 86 ng/site CRF–SAP injected (n¼3) rats. The 86 ng/site (172 ng
CRF1 expressing cells in the NI. Scale bars are 100 μm.NI and relaxin-3 remain largely undetermined but intri-
guing reports have been published in the past decade
demonstrating the alleged role of the NI/relaxin-3/RXFP3
system in feeding behaviour (McGowan et al., 2006; McGowan
et al., 2005), stress (Burazin et al., 2002; Smith et al., 2012),
anxiety (Watanabe et al., 2011) and cognition (Cervera-Ferri
et al., 2011; Farooq et al., 2013; Ma et al., 2009). Recent studies
show c-Fos expression in the nucleus incertus occurs in
response to acute antipsychotic treatments in rats (Rajkumar
et al., 2013) and polymorphisms in human relaxin-3 and RXFP3
associated with metabolic disturbances in patients with schizo-
phrenia treated with antipsychotic drugs (Munro et al., 2012).
Thus the study of the NI and relaxin-3 is an exciting new
frontier in behavioural neuroscience.
A strategy to achieve potent and selective lesioning of
target brain structures has been to utilise cell-surface protein
binding peptides or antibodies conjugated with saporin, a
monomeric ribosomal inactivating protein (Heckers et al.,
1994; Li et al., 2008; Thorpe et al., 1985; Waite et al., 1994).
Selectivity is achieved because, as a ribosomal toxin, the
saporin is only toxic when internalised by the corresponding
receptor. The corticotropin releasing factor (CRF)–saporin
conjugate toxin, used in the present study, is expected to
selectively ablate CRF1 expressing cells (Hummel et al., 2010;
Maciejewski-Lenoir et al., 2000). On the premise that relaxin-3
expressing neurons in the NI predominantly co-express CRF1
receptors (Tanaka et al., 2005), the present investigation
attempted to establish a method for selective ablation of
the NI using the CRF–saporin conjugate.. Images show representative examples of the CRF1 positive
rin injected (n¼3), (C) 43 ng/site CRF–SAP injected (n¼3) and
in total) dose of CRF–SAP produced the greatest reduction in
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Out of the total of 76 rats that underwent the surgical
procedure, 43 receiving CRF–saporin and 33 serving as various
controls, no mortality attributable to the CRF–saporin lesionFig. 2 – Speciﬁcity of the CRF RI/II antibody in the NI. (A) Repres
staining of the NI in a rat (n¼3). (B) Representative example of im
the CRF RI/II antibody with a 10 relative concentration of CRF
peptide blocks the immunoﬂuorescence staining demonstrating
Fig. 3 – RT-PCR and real-time PCR analysis of CRF–saporin lesion
of blank saporin, while lesions of the NI were produced by injec
the decreased expression of CRF1, relaxin-3 (RLN3) and GAD65 in
(n¼4). Equivalent expression of TPH2 indicated that CRF–SAP ta
densitometry analysis of the DNA gel relative to beta-actin. (C) R
and TPH2 mRNA expression changes between sham- (n¼4) and
expression decreased signiﬁcantly after CRF-saporin targeted le
lesion. Data are expressed as mean7SEM. *po0.05,**po0.01, ***was observed. Two rats were euthanised under veterinary
advice because of an unrelated infection and a case of
malocclusion of the incisors. In one experiment, post-
surgical weight gain was monitored daily over 14 days but
there was no signiﬁcant difference in weight gain between
the sham- and NI-lesioned rats (n¼8 per group, n.s.).entative example of CRF RI/II antibody immunoﬂuorescence
munoﬂuorescence staining after overnight preabsorption of
blocking peptide (n¼3). The preabsorption with blocking
speciﬁcity of the antibody. Scale bars are 100 μm.
ing of NI neurons. Sham lesions were produced by injection
tion of CRF–saporin. (A) Representative DNA bands showing
the NI-lesioned rats (n¼4) compared to sham-lesioned rats
rgeted only the CRF1 positive cells. (B) Semi-quantitative
eal-time RT-PCR analysis of CRF1, relaxin-3 (RLN3), GAD65
NI-lesioned (n¼4) groups. CRF1, relaxin-3 and GAD65 mRNA
sioning. TPH2 mRNA expression was not affected by the
po0.001.
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expressing cells
To determine an appropriate dose of CRF–saporin, 40 , 20
and 10 dilutions of the original stock solution of CRF–
saporin were infused separately into the NI of rats. CRF1
immunoﬂuorescence staining results showed that infusion of
172 ng of CRF–saporin was sufﬁcient to bring about a loss in
CRF1 expressing cells in the NI (Fig. 1A–D). This dose is
therefore used for the subsequent experiments. The speciﬁ-
city of the CRF RI/II antibody was assessed by preabsorption
of the antibody with the CRF blocking peptide, which abol-
ished CRF1 staining in the NI of naïve rats (Fig. 2A–B).
2.2. CRF–saporin selectively targets and ablates CRF1
positive cells
RT-PCR analysis showed that the NI-lesioned rats had a
signiﬁcant reduction in the expression of CRF1 receptors
compared to the sham-lesioned group. As hypothesised,
corresponding decreases in the expression of relaxin-3 and
GAD65 were also observed in the NI-lesioned rats (Fig. 3A).
TPH2 expression was unaltered in both the sham and
NI-lesioned group as seen in the densitometry analysis of
the PCR bands (Fig. 3B). In a separate group of animals, a real-
time PCR analysis showed that the CRF1, relaxin-3 and GAD65
mRNA expression in NI-lesioned rats was 0.004-, 0.02- and
0.07 fold relative to the sham-lesioned controls while TPH2
mRNA levels remained almost the same in both sham- and
NI-lesioned rats (Fig. 3C).
The protein expression assessed by western blotting of
CRF1, pro-relaxin-3, GAD65 and TPH2 was similar among the
naïve, saline injected, true sham (surgery but no infusion)
and sham-lesioned (blank saporin infusion) groups (Fig. 4A
and B). However, protein levels of CRF1 receptor was con-
siderably reduced in the NI-lesioned rats. There was also a
consistent decrease in the levels of pro-relaxin-3 in the NI-
lesioned rats as compared to the sham-lesioned rats (Fig. 4A).
The same set of samples was also checked for GAD65 and
TPH2 protein levels. A signiﬁcant decrease in the expression
of GAD65 was also observed in the NI-lesioned rats while
TPH2 protein levels remained unchanged. Densitometry ana-
lysis of the western blot demonstrated a statistically signiﬁ-
cant reduction in CRF1 (approximately 54%), pro-relaxin-3
(approximately 53%) and GAD65 (approximately 64%) protein
expression (Fig. 4B).
Further conﬁrmation of the lesion through immunoﬂuor-
escence labelling veriﬁed the loss of CRF1 receptor positive
cells in the NI of the NI-lesioned rats as compared to the
sham-lesioned rats (Fig. 5A and B). Similarly, relaxin-3
expressing cells also decreased considerably in the NI-
lesioned rats (Fig. 5D). Examination of the TPH2 expression
revealed that TPH2 positive cells lined the midline of the NI
and were unaffected by the lesioning procedure (Fig. 5E and F).
Positive CRF1 staining of the nearby locus coeruleus (LC) in
both sham- and NI-lesioned rats was also detected (Fig. 5G
and H). Immunostaining for the glial cell marker, glial ﬁbrillary
acidic protein (GFAP), showed up-regulation of glial cells in the
NI of both sham-lesioned and NI-lesioned rats at 14 days after
surgery (Fig. 6).2.3. CRF–saporin in the NI decreases levels of relaxin-3
in the medial septum
The levels of pro-relaxin-3 in the MS in naïve, saline, true
sham, sham- and NI-lesioned rats were assessed by western
blotting. A decrease in relaxin-3 levels was observed in the
MS of NI-lesioned rats (Fig. 7A). Densitometry analysis of the
blots showed an approximately 90% decrease in pro-relaxin-3
levels (Fig. 7B).2.4. NI-lesioned rats displayed increased freezing in cued
fear conditioning
The NI-lesioned and sham-lesioned rats were tested in a cued
fear conditioning paradigm. The rats were ﬁrst exposed to
tone-shock pairing and subsequently freezing behaviour in
response to the tone was assessed 24 h later. To determine if
the NI-lesioned rats had any locomotor deﬁcits, the total
distance travelled by the sham- and NI-lesioned rats were
measured during the 15 min habituation phase. There was a
slight but insigniﬁcant decrease in the distance covered by
the NI-lesioned rats (Fig. 8A) possibly due to the increased
periods of freezing observed during this phase (Fig. 8B).
No signiﬁcant difference between the percentage of freezing
between sham- and NI-lesioned rats was observed during the
tone-shock training phase (Fig. 8C), for 2 min before (Fig. 8D)
and during the 30 s tone at the 24 h test phase (Fig. 8D).
However, NI-lesioned rats displayed signiﬁcantly greater
freezing behaviour than the sham-lesioned rats in the 5 min
period following the tone during the test phase (Fig. 8D).3. Discussion
We describe a method to ablate the NI neurons. CRF-saporin,
lesioning neither caused mortality nor alteration in feed and
water consumption, which is in agreement with the ﬁndings
on relaxin-3 knockout mice (Smith et al., 2012; Smith et al.,
2009; Watanabe et al., 2011). Our results show that infusion of
172 ng of CRF–saporin was sufﬁcient to bring about a sig-
niﬁcant loss in CRF1 expressing cells in the NI. This was in
accordance to the ﬁndings by Pascual's group where 1–2 mg of
CRF–saporin injected ICV resulted in a signiﬁcant loss in CRF1
positive cells in the fundus of the striatum (FS) and lateral
septum (LS) (Pascual and Heinrich, 2007), suggesting that
CRF–saporin was able to target and permanently silence
CRF1 expressing cells in the brain. Unconjugated saporin did
not affect expression of CRF1 as seen in the sham-lesion rat
group, which was in agreement with the notion that the
saporin protein alone does not bind to any receptors and
cannot be taken in by the cells (Stirpe et al., 1983;
Maciejewski-Lenoir et al., 2000).
Previous evidence has shown that all relaxin-3 expressing
cells in the NI co-express CRF1 and can be activated by ICV
administration of CRF (Tanaka et al., 2005; Banerjee et al.,
2010), thus this study investigated the expression of relaxin-3
in the NI cells after the CRF-saporin targeted lesion. The
consistent decrease in relaxin-3 expression corresponded to
the ﬁndings that the NI cells express both CRF1 and relaxin-3.
Fig. 4 – Western blot analysis of CRF–saporin lesioning of NI neurons. The naïve group (n¼3) did not undergo any surgical
procedures. Saline rats (n¼3) received bilateral injections of 0.2 ll of saline. True sham lesions (n¼3) were produced by
inserting the needle containing CRF-SAP into the NI without infusion. Sham lesions were produced by injection of blank
saporin (n¼6) while lesions of the NI (n¼7) were produced by injection of CRF–saporin. (A) Representative western blot bands
showing the decreased levels of CRF1, pro-relaxin-3 (Pro-RLN3) and GAD65 in the NI-lesioned rats. The absence of change in
the expression of TPH2 indicated that CRF–saporin targeted only the CRF1 positive cells. (B) Semi-quantitative densitometry
analysis of the western blot relative to actin. Data are represented as mean7SEM. *po0.05, **po0.01, ***po0.001.
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one of the known projection targets of the NI, the MS, these
data indicated that this lesion model is a possible tool for the
study of relaxin-3 circuitry in the brain. Our lesion model also
demonstrated a compelling decrease in GAD65 expression, a
known indicator of GABAergic neurons. Relaxin-3 neurons in
the NI were known to co-express GAD65 (Ma et al., 2007), an
important indication that the neurotransmission from the NI
is inhibitory. Thus the resulting loss in GAD65 expression
reinforced the ﬁndings that NI neurons are GABAergic and
also provides an additional veriﬁcation that CRF–saporin
lesions the NI neurons.
The present method did not completely lesion the NI but was
sufﬁcient to produce a clear behavioural deﬁcit. It might be
possible to produce lesions of the NI to a greater extent by
injecting greater volumes or concentrations of CRF–saporin.
However, CRF1 receptors are also present in other nearby
structures such as the LC and there is a risk that the selectivity
of the lesion will be compromised. Moreover, the NI spans only
around 700 μm in the anterior–posterior aspect and hencemultiple injections can cause physical injury to the cells, which
is undesired. The NI and pontine raphe nucleus are both found
caudal to the 5HT-neurons of the dorsal raphe nucleus.
It was previously reported that distributions of 5HT-positive
neurons and relaxin 3-expressing neurons intermingled but did
not overlap (Tanaka et al., 2005). In our lesion model, expression
of TPH2 was unaffected by CRF–saporin infusions and TPH2 cells
lining the midline of the NI were intact even at 14 days after the
procedure. This ﬁnding reiterates the speciﬁcity of CRF–saporin
in targeting only the cells that express the CRF1 receptor.
A recent paper reported that electrolytic lesion of the nucleus
incertus retards extinction of auditory conditioned fear (Pereira
et al., 2013). However, electrolytic lesions lack cellular selectivity
and may damage ﬁbres of passage. Here we demonstrated that
CRF–saporin selectively targets and ablates CRF1 positive cells
while leaving cells without the receptor unharmed, indicating
the speciﬁcity. Moreover, earlier reports showed that CRF–
saporin had a greater binding afﬁnity to CRF1 as compared to
CRF2α receptors (Maciejewski-Lenoir et al., 2000), rationalising the
use of CRF–saporin to selectively lesion the NI. Moreover, while
Fig. 5 – Immunoﬂuorescence histochemical analysis of CRF–saporin lesioning of NI neurons. Sham lesions were produced by
injection of blank saporin (n¼5) while lesions of the NI (n¼7) were produced by injection of CRF–saporin. Representative
photomicrographs show reduction of (B) CRF1 receptors and (D) relaxin-3 (RLN3) positive cells in NI-lesioned rats compared to
sham-lesioned rats (A) and (C), respectively. Presence of TPH2 positive cells in both (E) sham- and (F) NI-lesioned groups
indicated that CRF–saporin was speciﬁc to CRF1 receptor positive cells. Positive CRF1 staining of the nearby locus coeruleus
(LC) cells in both (G) sham- and (H) NI-lesioned groups showed that the lesion was restricted to the NI. The presence of the
adjacent mesencephalic trigeminal nucleus (Me5) conﬁrms the anatomical localisation of LC. Scale bars are 100 μm.
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Fig. 6 – Representative photomicrographs of GFAP staining in the NI of (A) naïve (n¼3), (B) sham-lesioned (n¼3) and (C) NI-
lesioned rats (n¼3) 14 days after the lesion. There is up-regulation of GFAP in both sham- (B) and NI-lesioned rats (C). Scale
bars are 100 μm.
Fig. 7 – Relaxin-3 expression in medial septum was
determined by western blotting following CRF–saporin
targeted lesioning. The naïve group (n¼3) did not undergo
any surgical procedures. Saline rats (n¼3) received bilateral
injections of 0.2 ll of saline. True sham lesions were
produced by inserting the needle containing CRF–saporin
into the NI without infusion. Sham lesions were produced
by injection of blank saporin (n¼3) while lesions of the NI
(n¼3) were produced by injection of CRF–saporin.
(A) Representative western blot bands showing the
decreased expression of pro-relaxin-3 (Pro-RLN3) in the MS
of the NI-lesioned rats. (B) Semi-quantitative densitometry
analysis of the western blot relative to actin. Data are
represented as mean7SEM. *po0.05.
b r a i n r e s e a r c h 1 5 4 3 ( 2 0 1 4 ) 1 7 9 – 1 9 0 185the NI strongly expresses CRF1 in the rat (Potter et al., 1994;
Bittencourt and Sawchenko, 2000; Van Pett et al., 2000) there is
no expression of CRF2 (Van Pett et al., 2000).
Although, the NI has been predicted to be involved in a
variety of psychiatrically relevant conditions andmanifestations,
including stress, anxiety, depression, feeding behaviour, arousal
and cognition (Ryan et al., 2011; Smith et al., 2011) these
speculations are largely founded on the studies that indirectlyinfer from RXFP3 distribution in rodent brain (Sutton et al., 2004),
relaxin-3-like immunoreactivity, ([125I] R3/I5) binding (Ma et al.,
2007; Sutton et al., 2004) and anatomical tract tracing of the
afferent and efferent connexions of the NI (Goto et al., 2001;
Hoover and Vertes, 2007; Olucha-Bordonau et al., 2003). Current
methods of studying the functions of the NI include electrical
stimulation (Farooq et al., 2013; Nunez et al., 2006), pharmaco-
logical activation with CRF (Farooq et al., 2013; Tanaka et al.,
2005) and electrolytic lesioning (Pereira et al., 2013) of the NI to
determine its putative modulatory role on mnemonic processing
and behaviour. As the NI consists mostly of relaxin-3 positive
neurons, numerous studies also use H3, relaxin-3, relaxin-3
agonist/antagonist, relaxin-3 knockout mouse models and silen-
cing relaxin-3 in NI neurons to study the various postulated
functions of the NI (Callander et al., 2012; Ma et al., 2009; Smith
et al., 2012; Smith et al., 2009; Watanabe et al., 2011). The present
method to perturb the NI/relaxin-3 system using CRF-saporin is
expected to open an additional approach for research to under-
stand relevance of the NI/relaxin-3 system in behavioural
neuroscience.4. Experimental procedure
4.1. Animals and surgery
Male Sprague–Dawley rats (270–290 g) were procured from the
Centre for Animal Resources (CARE), National University of
Singapore, were maintained under standard housing condi-
tions (2172 1C, 12 h light-dark cycle and ad libitum food and
water). All experimental procedures were approved by the
Institutional Animal Care and Use Committee (IACUC),
National University of Singapore, and were in accordance
with the guidelines of the National Advisory Committee for
Laboratory Animal Research (NACLAR), Singapore, and the
Guide for the Care and Use of Laboratory Animals, National
Research Council of the National Academies, USA. Rats were
anaesthetised with an intraperitoneal injection of a ketamine
(75 mg/kg) and xylazine (10 mg/kg) cocktail, placed in a
stereotaxic frame and burr holes were drilled on the skull at
the coordinate corresponding to the NI (AP: 9.7 mm and ML:0-
0.1 mm) (Paxinos and Watson, 2007) calculated from the
bregma. Bilateral injections of 0.2 ml/site made 7.5 mm ventral
to the surface of the skull delivered 21.5 ng, 43 ng or 86 ng/site
Fig. 8 – Effect of NI lesioning on behaviour of rats in a cued fear conditioning paradigm. (A) Total distance travelled by sham-
lesioned (n¼10) and NI-lesioned (n¼8) rats in the fear conditioning chambers and (B) freezing behaviour during the four days
of 15 min habituation. (C) Shows the mean percentage freezing response during the training phase, while (D) and (E) show the
mean percentage freezing of rats for two minutes before and during the 30 s tone of the test phase (24h after the training). The
mean percentage freezing time following the tone during the test phase (F) showed that NI-lesioned rats exhibit a longer
freezing time compared to sham-lesioned rats. All data are represented as mean7SEM, *po0.05, ***po0.001.
b r a i n r e s e a r c h 1 5 4 3 ( 2 0 1 4 ) 1 7 9 – 1 9 0186of CRF–saporin or blank saporin (Advanced targeting Sys-
tems, USA) over 5 min. The needle was left in place for 5 more
minutes before withdrawal. The scalp was sutured and the
rat was allowed a rehabilitation period of 14 days before any
experiments were carried out. Saline rats (n=3) received
bilateral injections of 0.2 ml of saline. True sham lesions were
produced by inserting the needle containing CRF–saporin into
the NI without infusion. Sham lesions were produced by
injection of blank saporin (n¼6) while lesions of the NI (n¼7)
were produced by injection of CRF–saporin. Subsequently, the
brains were freshly harvested (for RT-PCR, real-time PCR orwestern blot) or harvested after transcardial perfusion (for
immunoﬂuorescence studies on free ﬂoating sections) to
check for the extent of the lesion. To determine if the lesion
of the NI had an effect on behaviour, a separate group of
sham-lesioned (blank saporin) and NI-lesioned (CRF–saporin)
rats were subjected to a fear conditioning paradigm.
4.2. Perfusion ﬁxation and fresh tissue harvest
Rats were anaesthetised with an overdose of pentobarbital
prior to transcardial perfusion with 0.9% saline, followed by
b r a i n r e s e a r c h 1 5 4 3 ( 2 0 1 4 ) 1 7 9 – 1 9 0 1874% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4). The
brain was removed immediately and post-ﬁxed overnight at
4 1C and then saturated with 30% sucrose in phosphate-
buffered saline (PBS). Free ﬂoating sections (30 mm) were
obtained with a vibratome (Leica Microsystems, Germany).
For qPCR and western blot analysis, the brains were removed
immediately following anaesthesia and 500 mm sections col-
lected using a rat brain matrix (Roboz Surgical, USA). The
position of the NI and MS were conﬁrmed under light
microscope, and then collected with a Harris Uni-CoreTM
1 mm micro-punch (Ted Pella Inc, USA) for further analysis.4.3. Preparation of mouse anti-relaxin-3 antibody
To prepare the mouse anti-relaxin-3 antibody, HK4-144-10
cells (Kizawa et al., 2003) were obtained from the Interna-
tional Patent Organism Depository (IPOD), National Institute
of Advanced Industrial Science and Technology (AIST), Japan,
and ﬁrst cultured in an antibiotic free GIT medium (Wako
Pure Chemicals Industries Ltd., Japan). The recovered hybri-
doma cells were then allowed to grow vigorously to a log
phase. The viability of the cells (490%) was determined
before harvesting and freezing for ascities production. Mice
were ﬁrst inoculated intraperitoneally with monoclonal
antibody-producing hybridoma cells; thereafter, the ascites
ﬂuid was collected and puriﬁed (1st Base, Singapore, ProSci
Incorporated, USA). Further puriﬁcation with Protein A agar-
ose (Thermo Scientiﬁc, USA) and elution with 0.1 M citrate
buffer containing 0.05% sodium azide were carried out. The
eluate was concentrated in a centrifugal ﬁlter unit (Millipore,
USA), washed with sterile phosphate buffered saline (PBS)
and stored as a 1 mg/ml stock containing 0.05% sodium azide
and 0.1% glycerol.4.4. Immunoﬂuorescence histochemistry
Sections were immunostained with a primary antibody solution
which contained goat anti-CRF RI/II antibody (SC1757, 1:1000,
Santa Cruz, USA), mouse anti-relaxin-3 antibody (1:1000), rabbit
anti-tryptophan hydroxylase 2 (TPH2) antibody (AB5572, 1:1000,
Chemicon, USA) or rabbit anti-glial ﬁbrillary acidic protein (GFAP)
antibody (Z0334, 1:1000, Dako, Denmark). Stained sections were
subsequently visualised with donkey anti-goat Alexa Fluor 555
(1:400), donkey anti-mouse Alexa Fluor 488 (1:400) or goat anti-
rabbit Alexa Fluor 488 (1:400) secondary antibodies, after which
slides were washed and mounted using Prolong Antifade with
DAPI (Invitrogen, Singapore) and viewed with a ﬂuorescence
microscope. The CRF RI/II polyclonal antibody used here was
raised against the C-terminus of human CRF1, which is con-
served across rat and mouse CRF1. Its speciﬁcity has been
demonstrated previously by Chen et al. (2000) in experiments
in which pre-incubation with the antigenic peptide abolished
CRF1 signals in western blots and staining in mouse brain
sections. In mouse heart sections known to express only CRF2,
no staining was observed (Chen et al., 2000). To evaluate the
speciﬁcity of this antibody in the NI neurons, a 10 relative
concentration of the CRF blocking peptide (C-20P, Santa Cruz,
USA) was pre-incubated with a 1:1000 dilution of the antibody
overnight at 4 1C. NI sections were then incubated in thissolution overnight and then further processed for CRF RI/II
staining.
4.5. Reverse transcriptase and real-time polymerase chain
reaction
Total RNA was extracted from the tissue and puriﬁed accord-
ing to the manufacturer's instructions for PureLink RNA mini
kit (Invitrogen, Singapore). The amount of RNA was quanti-
ﬁed with a NanoDrop UV–vis spectrophotometer (Thermo
Scientiﬁc, USA). Approximately 1 mg of total RNA was reverse
transcribed with oligo(dT) primers using ImProm-IITM Reverse
Transcription system (Promega, USA). The PCR reaction was
performed using the following sets of primers: CRF1 forward
primer 5'-ACC GAC CGT CTG CGC AAG TG-3', reverse primer
5'-AGC GGA GCG GAC CTC ACT GT-3' (453 bp expected band
size); relaxin-3 forward primer 5'-CTG CTG CTG GCT TCC TGG
GCT CTC CTC GGG GCT CT-3', reverse primer 5'-TCG CTG GCC
AGG TGG TCT GTA TTG GCT TCT CCA TCA-3' (218 bp
expected band size) (Chen et al., 2005); GAD65 forward primer
5'-GAA CAG CGA GAG CCT GGT-3', reverse primer 5'-CTC TTG
AAG AAG CTC ATT GG-3' (362 bp expected band size); TPH2
forward primer 5'–TAA ATA CTG GGC CAG GAG AGG-3',
reverse primer 5'-GAA GTG TCT TTG CCG CTT CTC-3'
(132 bp expected band size); and β-actin forward primer
5'-ATC CTG AAA GAC CTC TAT GC-3', reverse primer
5'-AAC GCA GCT CAG TAA CAG TC-3' (287 bp expected band
size). The PCR conditions were conducted at 94 1C for 5 min,
30 cycles of 94 1C for 30 s, 60–65 1C for 1 min, 72 1C for 1 min
followed by 10 min at 72 1C. The PCR products were then
separated in 1.5% agarose gel, stained with ethidium bro-
mide, and then visualised under UV irradiation.
Real-time RT-PCR ampliﬁcation on a separate group of
sham- (n¼4) and NI-lesioned (n¼4) was carried out using the
ViiA 7 Real-time RT-PCR system (Applied Biosystems, USA)
with SYBR green PCR master mix (Applied Biosystems, USA)
with the following gene-speciﬁc primers: CRF1 forward primer
5'-ACG ACA AAC AAT GGC TAC CG-3', reverse primer 5'-GCA
GTG ACC CAGGTA GTT GA-3'; relaxin-3 forward primer 5'–CCC
TAT GGG GTG AAG CTC TG-3', reverse primer 5'-CCA GGT
GGT CTG TAT TGG CT-3'; GAD65 forward primer 5'-GGG GTG
GAG GGT TAC TGA TG-3', reverse primer 5'-ACC CAT CAT
CTT GTG GGG AT-3'; TPH2 forward primer 5'-GCC TTT GCA
AGC AAG AAG GT-3', reverse primer 5'-CGC CTT GTC AGA
AAG AGC AT-3'; and β-actin forward primer 5'-ATC CTG AAA
GAC CTC TAT GC-3', reverse primer 5'-AAC GCA GCT CAG
TAA CAG TC-3'. β-actin was used as an internal control. The
PCR conditions were an initial incubation of 50 1C for 2 min
and 95 1C for 10 min followed by 40 cycles of 95 1C for 15 s and
59 1C for 1 min.
4.6. Western blot
Fresh NI/MS tissue was dissected and lysed with a radio-
immunoprecipitation assay (RIPA) buffer (150 mM sodium
chloride, 1.0% Triton X-100, 0.5% sodium deoxycholate, 0.1%
sodium dodecyl sulphate, 50 mM Tris, pH 8.0). Proteins were
ﬁrst quantiﬁed with a Pierce bicinchoninic acid assay (BCA)
kit (Thermo Scientiﬁc, USA), separated on a 12% sodium
dodecyl sulphate (SDS)-PAGE and then transferred onto a
b r a i n r e s e a r c h 1 5 4 3 ( 2 0 1 4 ) 1 7 9 – 1 9 0188polyvinylidene ﬂuoride (PVDF) membrane. The membrane
was blocked with 1% skim milk and incubated with a goat
anti-CRF RI/II (1:1000, Santa Cruz, USA), rabbit anti-GAD65
(AB5082, 1:1000, Millipore, USA), rabbit anti-TPH2 (1:1000,
Chemicon, USA) and rabbit anti-actin (A2066, 1:10 000,
Sigma-Aldrich, USA) or 5% Bovine Serum Albumin (BSA)
solution and incubated with mouse anti-RLX3 (1:2500) over-
night at 4 1C. The blot was then washed and incubated with a
HRP-conjugated anti-goat (1:5000), anti-rabbit IgG (1:5000) or
goat anti-mouse Alexa Fluor 488 (1:5000) for 1 h at room
temperature with agitation. The proteins were then detected
with a chemiluminescence kit. Protein expression levels were
normalised to actin.4.7. Fear conditioning
Sham- and NI-lesioned rats were subjected to a fear con-
ditioning paradigm (King and Williams, 2009) 14 days after
surgery. The rats were ﬁrst acclimatised to the room for 2 h
before the start of each session. Habituation to the fear
conditioning chambers (TSE Systems Inc., USA) was carried
out for 15 mins for 4 days before training. The training phase
consisted of a 2 min pause, and 6 repeats of 30 s tone with a
0.8 mA shock presented in the last 2 s of the 30 s tone. During
the test phase 24 h later, the tone was sounded for 30 s
without the shock. The time spent in freezing was recorded
for 5 min following the tone. Freezing was detected by an
array of infrared light beam sensors mounted 14 mm apart to
monitor the position and movement of the animal inside the
chamber (TSE Systems Inc., USA). All recordings were done
via the TSE Systems software. This programme uses an
averaging procedure to deﬁne the centre of gravity of the
rat. An instance of freezing was deﬁned as the animal not
moving for more than a threshold duration of 5 s. Percentage
freezing was calculated as the cumulative duration of freez-
ing as a percentage of total time.4.8. Analysis and statistics
RT-PCR gel and western blot images were analysed with
ImageJ. The density of each band was measured and normal-
ised to its corresponding actin band (RT-PCR: n¼4 each for
sham and NI-lesioned; western blot: n¼3 for naïve, n¼3 for
saline, n¼3 for true sham, n¼6 for sham-lesioned and n¼7
for NI-lesioned). The densitometry data was statistically
analysed with unpaired t tests (GraphPad Prism, USA) com-
paring sham-lesioned and NI-lesioned groups for each pro-
tein. For the real-time PCR (n¼4 each for sham and NI-
lesioned), the ampliﬁed transcripts were quantiﬁed using
the comparative CT method (Livak and Schmittgen, 2001),
with the formula for relative fold change¼2–ΔΔCT. The means
were analysed with unpaired t tests (GraphPad Prism, USA).
Freezing behaviour (threshold set at 3 s) of the sham-lesioned
(10) and NI-lesioned (n¼8) rats was recorded in 30 s epochs
for a total of 5 min. Total percentage freezing time was
calculated and analysed with an unpaired t test (GraphPad
Prism, USA). The data were expressed as mean7SEM.Acknowledgements
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